Interchangeability, switchability, and substitution of biosimilar products

Biosimilar Drug Product Development

Volumn , Issue , 2017, Pages 283-296

  Declerck, Paul ^a   Endrenyi, Laszlo ^b   Chow, Shein Chung ^c  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY OF TORONTO   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042308730     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781315119878     Document Type: Chapter

References (42)

1. Allen & Overy. (2014) Biosimilar substitution in France: no way back? The Lawyer, January 10, 2014. Available from: http://www.thelawyer.com/brie_ngs/biosimilar-substitutionin-france-no-way-back/3014733.article.
2. Anderson S, Hauck WW. (1990) Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 18(3), 259-273.
3. British Society for Rheumatology. (2015) Position statement on biosimilar medicines. Available from: http://www.rheumatology.org.uk/about_bsr/press_releases/bsr_supports_ the_use_of_biolsimilars_but_recommends_measures_to_monitor_safety.aspx.
4. Cauchi R. (2016) State laws and legislation related to biological medications and substitutions of biosimilars. National Conference of State Legislatures (NCSL), Washington, DC. Available from: http://www.ncsl.org/research/health/state-laws-and-legislationrelated-to-biologic-medications-and-substitution-of-biosimilars.aspx#Mandatory.
5. Chow SC. (2013) Design and Analysis of Biosimilar Studies. Chapman and Hall/CRC Press, Taylor & Francis, New York.
6. Chow SC, Liu JP. (2008) Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd edition. Chapman and Hall/CRC Press, Taylor & Francis, New York.
7. Declerck PJ, Darendeliler F, Góth M, et al. (2010) Biosimilars: controversies as illustrated by rhGH. Current Medical Research and Opinion 26, 1219-1229.
8. Declerck P, Farouk-Rezk M, Rudd PM. (2016) Biosimilarity versus manufacturing change:two distinct concepts. Pharmaceutical Research 33, 261-268.
9. Declerck P, Mellstedt H, Danese S. (2015) Biosimilars: terms of use. Current Medical Research and Opinion 31, 2325-2330.
10. Declerck PJ, Simoens S. (2012) European perspective on the market accessibility of biosimilars. Biosimilars 2, 33-40.
11. Ebbers HC, Chamberlain P. (2014) Interchangeability. An insurmountable fifth hurdle? Generics and Biosimilars Initiative Journal 3(2), 88-93.
12. Ebbers HC, Muenzberg M, Schellekens H. (2012) The safety of switching between therapeutic proteins. Expert Opinion in Biology and Therapy 12(11), 1473-1485.
13. EMA. (2006) Guideline on similar biological medicinal products. The European Medicines Agency, evaluation of medicines for human use. EMEA/CHMP/437/04, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ guideline/2009/09/WC500003517.pdf.
14. EMA. (2009) Questions and answers on biosimilar medicines (similar biological medicinal products), London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf.
15. EMA. (2010) Guideline on the investigation of bioequivalence. European Medicines Agency, London, UK. January 20, 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf.
16. EMA. (2014) Guideline on similar biological medicinal products. London, UK, October 23, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
17. EMA. (2015) EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/004007/WC500200381.pdf.
18. Endrenyi L, Chang C, Chow SC, Tothfalusi L. (2013) On the interchangeability of biologic drug products. Statistics in Medicine 32(3), 434-441.
19. FDA. (2001) Guidance for industry: statistical approaches to establishing bioequivalence. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
20. FDA. (2013) Draft guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf.
21. FDA. (2015a) Scientific considerations in demonstrating biosimilarity to a reference product. United States Food and Drug Administration, Silver Spring, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
22. FDA. (2015b) Quality considerations in demonstrating biosimilarity to a reference protein product. United States Food and Drug Administration, Silver Spring, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf.
23. FDA. (2015c) Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. United States Food and Drug Administration, Silver Spring, MD. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf.
24. FDA. (2016) Approved drug products with therapeutic equivalence evaluations (Orange Book). Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm.
25. Federal Register. (2009) Biologics Price Competition and Innovation Act. fl7002(a)(2). Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/ucm216146.htm.
26. GPhA. (2015) GPhA and biosimilars council praise new state laws to allow automatic substitution for interchangeable biologics. Press release of Generic Pharmaceutical Association, Washington, DC, May 13, 2015. Available from: http://www.gphaonline. org/gpha-media/press/gpha-and-biosimilars-council-praise-new-state-laws-to-allowautomatic-substitution-for-interchangeable-biologics.
27. Health Canada. (2010a) Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs), Ottawa, ON. Available from: http://www.hc-sc. gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf.
28. Health Canada. (2010b) Questions and answers to accompany the final guidance for sponsors:information and submission requirements for subsequent entry biologics (SEBs). Question 15. Ottawa, ON, 2010. Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/notice-avis_seb-pbu_2010-eng.php.
29. Klein AV, Wang J, Bedford P. (2014) Subsequent entry biologics (biosimilars) in Canada:approaches to interchangeability and the extrapolation of indications and uses. Generics and Biosimilars Initiative Journal 3(3), 150-154.
30. NOR-SWITCH study. (2015) Clinical trials database, last updated November 25, 2015. Available from: http://clinicaltrials.gov/ct2/show/record/NCT02148640.
31. Ridder L, Waterman M, Turner D, et al. (2015) Use of biosimilars in paediatric inflammatory bowel disease: a position statement Journal of Pediatric Gastroenterology and Nutrition 61(4), 503-508.
32. Schall R, Luus H. (1993) On population and individual bioequivalence. Statistics in Medicine 12, 1109-1124.
33. Schiestl M, Stangler T, Torella C, et al. (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nature Biotechnology 29, 310-312.
34. Schuirmann DJ. (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 15, 657-680.
35. Scott BJ, Klein AV, Wang J. (2015) Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. Journal of Clinical Pharmacology 55(Suppl. 3), S123-S132.
36. Sheiner LB. (1993) Bioequivalence revisited. Statistics in Medicine 30, 1777-1788.
37. Stewart JJ, Agosto H, Litwin S, et al. (1997) A solution to the rheumatoid factor paradox:pathologic rheumatoid factors can be tolerized by competition with natural rheumatic factors. The Journal of Immunology 159, 1728-1738.
38. Thimmaraju PK, Rakshambikai R, Farista R, Jurulu K. (2015) Legislations on biosimilar interchangeability in the US and EU: developments far from visibility. GaBI Online posted:June 1, 2015. Available from: http://www.gabionline.net/Sponsored-Articles/Legislationson-biosimilar-interchangeability-in-the-US-and-EU-developments-far-from-visibility.
39. Tothfalusi L, Endrenyi L, Chow SC. (2014) Statistical and regulatory considerations in assessments of interchangeability of biological drug products. European Journal of Health Economics 15 (Suppl. 1), S5-S11.
40. Van Assche G, Vermeire S, Ballet V, et al. (2012) Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 61(2), 229-234.
41. Weise M, Bielsky MC, De Smet K, et al. (2012) Biosimilars: what clinicians should know. Blood 120, 5111-5117.
42. WHO. (2005) Draft revision on multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. World Health Organization, Geneva, Switzerland.